BWXT Medical, TRIUMF ink medical isotope production deal

2021 01 20 17 09 1785 Isotope Atom Space 400

BWXT Medical and Canada's particle accelerator center TRIUMF have executed a licensing and services agreement that will expand their existing medical isotope production partnership.

The agreement will enable BWXT Medical to manufacture actinium-225 (Ac-225)-based products for pharmaceutical companies developing targeted alpha therapeutics. After TRIUMF irradiates thorium-232 targets, BWXT will then process and produce high-purity Ac-225 for commercial sale, according to the vendor

Page 1 of 435
Next Page